Limited coverage criteria – aripiprazole monohydrate

Generic name

aripiprazole monohydrate

Brand

Strength

Form

Management of the manifestations of schizophrenia or related psychotic disorders (not dementia-related) in:

• Patients who have tried oral aripiprazole, risperidone or paliperidone, and
  • At least one other antipsychotic agent, and
  • Who continue to be inadequately controlled at maximally-tolerated doses

OR

• Patients who are currently receiving a conventional depot antipsychotic, and
  • Are experiencing significant side effects such as extrapyramidal symptoms or tardive dyskinesia

OR

• Patients with a history of non-adherence to antipsychotic medications resulting in important negative outcomes such as repeated hospitalizations

Indefinite